Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...

One challenge of using cell therapy to treat type 1 diabetes is that this approach requires chronic suppression of the immune system to prevent rejection of donor cells. A Vertex Pharmaceuticals ...

Vertex Pharmaceuticals (NDAQ: VRTX) stands today as a top 20 pharma company with over a $100 billion market cap. But this biotech beacon has ridden a bumpy path to its current perch and, along the way ...

Elsewhere, the company's Casgevy, approved some two years ago to treat two rare blood disorders, could also make commercial ...

Vertex Pharmaceuticals (VRTX) closed at $453.74 in the latest trading session, marking a -1.31% move from the prior day. This change lagged the S&P 500's daily loss of 0.14%. Meanwhile, the Dow ...

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a ...

Vertex’s new diabetes cell therapy has brought many surprises: first, the rush of excitement that followed new data from a single patient last year. And now, an FDA clinical hold on a phase 1/2 trial.

After another solid year that included 12% growth in the top line, Vertex has bumped up its compensation for CEO Reshma Kewalramani, M.D., to $21.5 million, according to the company’s proxy filing.

UTime (WTO) announced its Hong Kong subsidiary, UTime Technology, has officially signed a smart health device procurement ...